BioVie (BIVI US)

Analysis

Health Care • United States

BioVie Inc. is a clinical stage biotechnology company engaged in the discovery, development and commercialization of therapies targeting life-threatening complications of liver cirrhosis. The Company's initial disease target is ascites a condition impacting people globally. BioVie is based out of the United States.

Refresh

Company Presentation • 15 Sep 2026 20:30

Study result

Company Presentation • 13 Aug 2026 04:15

Study result

Company Presentation • 02 Jun 2026 19:00

Corporate presentation

Company Presentation • 01 Apr 2026 19:00

Corporate presentation

No more presentations

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00